Scientific article

Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction

Published inEuropean heart journal, vol. 31, no. 7, p. 815-823
Publication date2010

AIMS: To assess the prognostic value of anti-apolipoprotein A-1 (anti-apoA-1) IgG after myocardial infarction (MI) and its association with major cardiovascular events (MACEs) at 12 months and to determine their association with resting heart rate (RHR), a well-established prognostic feature after MI. Anti-apoA-1 IgG have been reported in MI without autoimmune disease, but their clinical significance remains undetermined. METHODS AND RESULTS: A total of 221 consecutive patients with MI were prospectively included, and all completed a 12-month follow-up. Major cardiovascular events consisted in death, MI, stroke, or hospitalization either for an acute coronary syndrome or heart failure. Resting heart rate was obtained on Holter the day before discharge under the same medical treatment. Neonate rat ventricular cardiomyocytes (NRVC) were used in vitro to assess the direct anti-apoA-1 IgG effect on RHR. During follow-up, 13% of patients presented a MACE. Anti-apoA-1 IgG positivity was 9% and was associated with a higher RHR (P = 0.0005) and higher MACE rate (adjusted OR, 4.3; 95% CI, 1.46-12.6; P = 0.007). Survival models confirmed the significant nature of this association. Patients with MACE had higher median anti-apoA-1 IgG values at admission than patients without (P = 0.007). On NRVC, plasma from MI patients and monoclonal anti-apoA-1 IgG induced an aldosterone and dose-dependent positive chronotropic effect, abrogated by apoA-1 and therapeutic immunoglobulin (IVIG) pre-incubation. CONCLUSIONS: In MI patients, anti-apoA-1 IgG is independently associated with MACE at 1-year, interfering with a currently unknown aldosterone-dependent RHR determinant. Knowing whether anti-apoA-1 IgG assessment could be of interest to identify an MI patient subset susceptible to benefit from apoA-1/IVIG therapy remains to be demonstrated.

  • Acute Coronary Syndrome/mortality
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Apolipoprotein A-I/*immunology
  • Arrhythmias, Cardiac/*diagnosis/physiopathology
  • Biological Markers/metabolism
  • Dose-Response Relationship, Immunologic
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Heart Failure/mortality
  • Heart Rate/immunology
  • Humans
  • Immunoglobulin G/*metabolism
  • Male
  • Middle Aged
  • Myocardial Infarction/*diagnosis/mortality/physiopathology
  • Myocytes, Cardiac/immunology
  • Prognosis
  • Prospective Studies
  • Rats
  • Rats, Wistar
  • Reference Values
  • Reproducibility of Results
  • Stroke/mortality
  • Treatment Outcome
Citation (ISO format)
VUILLEUMIER, Nicolas et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. In: European heart journal, 2010, vol. 31, n° 7, p. 815–823. doi: 10.1093/eurheartj/ehq055
Main files (1)
ISSN of the journal0195-668X

Technical informations

Creation05/23/2012 9:01:03 AM
First validation05/23/2012 9:01:03 AM
Update time03/14/2023 5:36:26 PM
Status update03/14/2023 5:36:26 PM
Last indexation02/12/2024 8:21:15 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack